References
- Trousseau A. Phlegmasia alba dolens. Clinique Médicale de l’Hôtel-Dieu de Paris. Paris, France: JB Ballière et Fils, 1865:654–712
- Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585–93
- Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809–15
- Lee AYY. Epidemiology and management of venous thromboembolism in patients with cancer. Thromb Res 2003;110:167–72
- Mandalà M, Ferretti G, Cremonesi M, et al. Venous thromboembolism and cancer: new issues for an old topic. Crit Rev Oncol Hematol 2003;48:65–80
- Otten HM, Mathijssen J, ten Cate H, et al. Symptomatic venous thromboembolismincancerpatientstreatedwithchemotherapy:an underestimated phenomenon. Arch Intern Med 2004;164:190–4
- Lee AYY, Levine M. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999;87:575–9
- Cook DJ, Mulrow CD, Haynes RB, et al. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med 1997;126:376–80
- Alderson P, Green S, Higgins JPT, et al. Cochrane Collaboration Handbook 4.2.1 [updated December 2003]. In: The Cochrane Library. Chichester, UK, John Wiley, 2004
- Nalysnyk L, Fahrbach K, Reynolds MW, et al. Adverse events in coronary artery bypass graft (CABG): a systematic review and analysis. Heart 2003;89;767–72